North Dakota MPJE Pharmacy Law Study Guide

1. Initial pharmacist licensure

A candidate can finish education, supervised experience, and examinations yet still lack authority to practice as a pharmacist in North Dakota. Treat licensure as a sequence: establish eligibility, submit the required application and supporting credentials, satisfy examination requirements, then confirm that the North Dakota Board of Pharmacy has issued an active pharmacist license. An examination result shows that one condition has been met; it is not the license itself. When assigning work, distinguish activities allowed under another valid credential, such as supervised intern work, from decisions reserved for a licensed pharmacist. Check the person’s actual status for the date and location of the shift, including any restriction, rather than relying on a diploma, score report, or anticipated approval. The same distinction matters when a candidate has received notice that an application is being processed.

Worked example: Mara has completed her degree and required examinations. On Monday, her North Dakota application still shows pending, although the pharmacy needs a pharmacist for the evening shift. The manager cannot count Mara as the pharmacist on duty. If she holds a valid intern registration, she may perform only permitted intern work under the required supervision. The manager arranges an actively licensed pharmacist and checks Mara’s status again before changing her role.

Watch the distinction: Passing the last examination does not automatically activate a pharmacist license. The decisive event is issuance of the required North Dakota authority, with an active status and any conditions observed.

Reference: [1]; [2]

2. Licensure by an existing license

An existing license supplies evidence of professional qualifications and practice history, but each state controls its own pharmacist authorization. A pharmacist licensed elsewhere may use a licensure transfer pathway and submit information about education, examinations, and standing to North Dakota. The receiving state still decides whether its requirements are met and whether a license will issue. Read “transfer” as a method of applying, not as permission to begin work across the border. Check whether the other license is current and unrestricted, whether any discipline must be disclosed, and whether North Dakota has completed its decision. A pharmacy also needs to assign work according to the credential the pharmacist actually holds in North Dakota. The National Association of Boards of Pharmacy offers licensure services, while state authorization remains a Board decision.

Worked example: Eli has an active Minnesota pharmacist license and has submitted a North Dakota transfer application. A Fargo pharmacy puts him on next week’s schedule as its sole pharmacist. His Minnesota standing may help establish eligibility, but the pending application supplies no North Dakota pharmacist authority. The schedule must be changed until North Dakota issues the needed license; training or other work must stay within whatever separate authorization Eli holds.

Watch the distinction: A neighboring state’s license is not a regional license. Neither employment at a North Dakota pharmacy nor submission through a transfer service completes the receiving state’s licensure decision.

Reference: [1]; [2]

3. Renewal and active status

Renewal has two separate parts: the professional meets the renewal conditions, and the licensing record reflects authority for the next practice period. Payment, a submitted form, and an employer’s reminder are evidence of steps taken; none should be mistaken for a confirmed active status when the record says otherwise. Before a shift, compare the worker’s identity, license category, expiration or status, and any restrictions with the duties assigned. If a portal shows expired or inactive, investigate a possible processing delay or missing requirement before scheduling independent pharmacist work. Keep a record of the resolution so another scheduler does not repeat the error. This reasoning applies even if the pharmacist expects approval soon. The patient facing legal responsibility of a pharmacist cannot be supplied retrospectively by a later renewal.

Worked example: Noor pays a renewal fee on Friday. On Monday, the license record still reads expired, and the manager planned to have Noor open the pharmacy alone. The manager checks the Board record, asks for resolution of the discrepancy, and assigns an actively licensed pharmacist meanwhile. A payment receipt documents Noor’s attempt to renew but does not establish Monday’s authority to perform independent pharmacist duties.

Watch the distinction: A submitted renewal is not proof that active status continued. The practical question is what authority exists when the pharmacist performs the work, including any unresolved lapse or restriction.

Reference: [1]

4. Reinstatement after a lapse

A long lapse can change the route back to practice. Ordinary renewal generally continues an existing authorization through its regular cycle; reinstatement addresses a license that has ceased to provide current authority. The Board may need to evaluate the length and circumstances of the lapse, prior standing, competence, and any conditions before allowing practice again. Do not assume that paying several missed fees restores the prior license automatically. First identify the current status and the Board’s applicable return pathway, then complete its requirements and verify issuance or reactivation. This protects patients because practice skills, drug systems, and legal requirements may have changed while the pharmacist was away. The same reasoning distinguishes reinstatement from a new application: the correct process follows the status and governing rules, not the former license holder’s preferred label.

Worked example: Sam last practiced in North Dakota several years ago and stopped renewing. A pharmacy asks Sam to cover tomorrow’s shift because an old wall certificate is still available. The certificate proves only past licensure. Sam must use the applicable return process and wait for active authority. The pharmacy arranges another pharmacist for tomorrow and may plan Sam’s return after status and any practice conditions are resolved.

Watch the distinction: A former license is historical evidence, not a standing permission to resume. A lengthy lapse may trigger requirements different from routine renewal, even when the person once practiced without discipline.

Reference: [1]

5. Changes in professional status

A license record must identify and reach the right professional. Changes in legal name, contact details, employment, or disciplinary standing may require separate reporting under the applicable North Dakota provisions. Renewal answers whether authority continues for another period; a change report keeps the Board’s current information accurate between renewals. For each event, identify what changed, who must report it, which record needs updating, and whether any supporting document is required. A name change may require identity evidence, while discipline elsewhere may call for disclosure of the underlying action, not just an address update. Employment changes can also affect a facility’s records or pharmacist-in-charge arrangements. Do not treat an employer’s personnel file as a substitute for a required professional filing. Clear records support notices, credential checks, and investigations.

Worked example: Rina’s license is active. She changes her legal name after marriage and moves to a different city in the same month. Her employer updates payroll, but that does not update the Board’s professional record. Rina submits the required identity and address changes through the Board’s process and confirms that the record matches her current information. She still completes her next renewal separately when due.

Watch the distinction: An active license does not make midcycle changes irrelevant. Waiting until renewal can leave identity or contact information wrong, and an employer’s update may not satisfy the pharmacist’s reporting duty.

Reference: [1]

6. Intern registration and experience

Intern status rests on eligibility and registration, not simply on enrollment or accumulated hours. Supervised experience is meant to develop professional skills while a pharmacist remains responsible for the supervision and decisions required by law. Analyze a proposed assignment in four steps: confirm the student’s current intern status, identify the task, identify the required supervisor and setting, and determine whether the activity can count as recognized experience. Hours earned in a permitted setting may advance a licensure application, but they do not convert the intern into an independent pharmacist. An intern may take a more active role than a technician where authorized, yet the boundary of intern practice remains distinct from full licensure. Keep records of experience that can be attributed to the correct period and supervisor.

Worked example: Leah is a registered intern with extensive supervised pharmacy hours. The only pharmacist leaves for an appointment, and a patient arrives with a prescription that needs clinical review. Leah’s accumulated hours do not let her act as the pharmacist on duty. The pharmacy waits for qualified coverage or follows a lawful alternative workflow. Her training record may support later licensure, but it does not expand today’s independent authority.

Watch the distinction: Completing experience hours is a qualification milestone, not a license. Intern registration and supervision must still cover the work being done, and pharmacist-only decisions remain with an authorized pharmacist.

Reference: [1]

7. Technician registration

Pharmacy technician work is regulated because preparation and data handling can affect the medicine a patient receives. Before a new employee processes prescriptions, check the applicable North Dakota technician credential, its active status, any training category or limitation, and the supervision required at the site. Experience as a cashier or in another state does not itself establish North Dakota technician authority. Separate front-store duties that do not involve regulated pharmacy work from prescription entry, counting, labeling, or other technical tasks. A person can learn the workflow through permitted observation and training, but the pharmacy must not treat a job title or pending application as a credential. Credential checks should be repeated when status changes or a training category ends, and assignments should match the worker’s actual authorization.

Worked example: A new hire, Owen, has two years of retail checkout experience but no North Dakota pharmacy credential. He can stock ordinary front-store merchandise and direct customers to the pharmacy counter. He is not assigned prescription entry or filling merely because he knows the register. The supervisor confirms the correct technician status and training arrangement before Owen begins regulated pharmacy tasks.

Watch the distinction: A job offer does not create technician registration. Nor does general retail experience establish permission to handle prescriptions; the task, credential category, status, and supervision all matter.

Reference: [1]

8. Technician task boundaries

Technicians can support accurate dispensing through technical work such as entering information, preparing labels, locating stock, and documenting steps within their authorized scope. The pharmacist retains clinical assessment and final responsibilities assigned to the pharmacist. A useful boundary test asks whether the decision requires interpreting patient-specific risk or deciding that a prescription is appropriate. Selecting stock by an already verified product identifier is technical; deciding whether a reported allergy permits use of that product is clinical. Alerts are signals to stop and route the issue, not buttons to clear for speed. A technician should preserve the facts that prompted concern, avoid telling the patient that the medication is safe, and give the pharmacist enough information to resolve it. This division works only when supervision and a genuine pharmacist review are present.

Worked example: Tess enters an amoxicillin prescription and selects the matching bottle. The system then displays a recorded penicillin reaction involving facial swelling. Tess stops the fill, leaves the alert visible, and tells the pharmacist what the profile says. The pharmacist assesses the history and prescriber’s plan before any release. Tess’s accurate stock selection does not resolve the allergy question.

Watch the distinction: A technician’s familiarity with a medicine does not authorize clinical override. An alert may prove harmless after review, but deciding that requires pharmacist judgment and a recorded resolution.

Reference: [1]

9. Delegation and supervision

Delegation is a decision about a person, a task, and the supervision available at that moment. Start with the worker’s active credential and any limits. Next ask whether the task may be delegated at all. Then determine what type of pharmacist supervision and verification the task requires before the product reaches the patient. A prepared label or counted quantity is an intermediate work product; it is not a dispensing decision. The pharmacist must have enough access to the prescription, product, profile, and work record to perform the required review. A busy pharmacist may allow authorized preparation to continue, but workload does not erase review points. Build the workflow so unresolved alerts, unclear directions, and mismatched products remain blocked until the authorized professional resolves them. The MPJE study guide can help frame similar role-boundary questions.

Worked example: A registered technician prints a label while the pharmacist is counseling another patient. The label states one tablet twice daily, but the entered order has an unresolved strength discrepancy. The technician can hold the prepared work for review under applicable supervision. The package cannot be released until the pharmacist resolves the discrepancy and completes the checks required for that prescription.

Watch the distinction: Delegation of preparation does not transfer final professional accountability. A pharmacist being physically present also does not automatically validate work the pharmacist has not actually reviewed.

Reference: [1]

10. Pharmacist-in-charge accountability

The pharmacist-in-charge, often called the PIC, is responsible for organizing a compliant pharmacy system. That includes suitable personnel assignments, training, record processes, drug security, and correction of recurring problems. The role is managerial and professional: a PIC should notice patterns, define workable controls, and confirm that staff follow them. Individual pharmacists still own their own clinical and dispensing decisions. When an error appears, ask both who handled the particular transaction and whether the system made similar errors likely. A missing controlled-substance record, for example, may require transaction correction, inventory reconciliation, staff retraining, and a check that the revised process works. Merely telling staff to be careful misses the control failure. Conversely, naming a PIC does not excuse a pharmacist who knowingly completed an improper transaction.

Worked example: An audit finds that several controlled-substance receipts lack the required entries. The PIC identifies which deliveries and staff are involved, reconciles stock, repairs the receipt workflow, and trains employees. A pharmacist who accepted one delivery still must explain and correct that transaction. The PIC’s system oversight and the pharmacist’s transaction responsibility exist at the same time.

Watch the distinction: The PIC is not a liability shield for every other pharmacist. Shared system duties and individual duties can both be implicated by the same missing record or unsafe practice.

Reference: [1]

11. Management transitions

A change in pharmacy management affects legal accountability, access to records, and continuity of supervision. When a PIC departs, determine who is qualified and willing to assume the role, when the change takes effect, what notice or application the Board requires, and whether the pharmacy can operate lawfully during any gap. Transfer custody of keys, controlled-substance records, inventory information, system access, open investigations, and pending corrective actions through a documented handoff. The departing professional should not remain nominally responsible after losing control, and the successor needs a reliable starting account of the operation. Ownership should update Board records and internal permissions rather than treating the event only as a staffing change. A timely transition also prevents employees from receiving conflicting instructions about who may supervise or approve work.

Worked example: The PIC resigns effective Friday at closing. The owner identifies a qualified replacement, checks the required Board change process, and records a handoff of inventory records, access credentials, and unresolved audit items. If the replacement cannot assume responsibility by Monday, the owner addresses the operating gap before opening. Keeping the former PIC’s name on a schedule would not supply actual oversight.

Watch the distinction: A staffed pharmacy does not necessarily have the required management arrangement. PIC changes can trigger separate notices and handoff duties even when another pharmacist is available to dispense.

Reference: [1]

12. Grounds for discipline

Professional discipline depends on conduct and risk, not simply on whether a patient was harmed. An isolated error calls for immediate patient protection, accurate correction, and process review. Repeated unsafe practice suggests a competence or supervision problem. Fraud and record falsification add intentional dishonesty; impairment raises fitness and patient-safety concerns; unlicensed activity concerns the legal authority to act at all. These categories can overlap, so examine the facts separately: what happened, who knew, what was recorded, whether a patient was exposed, and whether the conduct continued after warning. A pharmacist should preserve an honest audit trail when correcting an error. Erasing evidence can convert a correctable mistake into an integrity issue and make it harder to identify affected patients. Regulatory action may be distinct from employer discipline or civil liability.

Worked example: A pharmacist finds that a label says one tablet daily although the verified order says two. The pharmacy contacts the patient, assesses doses taken, corrects the record, and investigates the cause. If the pharmacist instead edits the original entry to make the error disappear, the inaccurate record creates a separate dishonesty concern even if the patient was unharmed.

Watch the distinction: No injury does not make an unsafe act acceptable, and an error does not automatically prove fraud. Intent, repetition, candor, and the steps taken after discovery change the analysis.

Reference: [1]

13. Complaints and misconduct reports

A complaint or observed misconduct requires a fact-based response. First protect any patients who may be affected; then preserve orders, profiles, audit logs, and firsthand observations before memories or records change. Escalate through the pharmacy’s appropriate channel and determine whether the facts trigger a Board or other regulator report under the applicable rules. Report what is known, what remains uncertain, and what protective action occurred. Repeated bypassing of clinical alerts is different from a single documented override after review: the pattern suggests that patients may have received medicines without assessment. Do not promise confidentiality that cannot be kept, or investigate by altering another professional’s records. A complaint process is meant to test conduct fairly while allowing urgent risks to be addressed. Internal escalation and external reporting can both be necessary.

Worked example: Nadia observes a colleague repeatedly release prescriptions after clearing interaction alerts without review notes. She identifies the affected transactions and ensures a qualified pharmacist assesses current patient risks. She preserves the system history, reports the pattern through the pharmacy’s process, and determines any required Board report. She states the observed facts rather than accusing the colleague of an unproven motive.

Watch the distinction: An internal report does not automatically satisfy a separate legal reporting duty. Equally, suspicion should not be presented as established fraud without checking records and protecting affected patients first.

Reference: [1]

14. Continuing education records

Continuing education is a documented condition of professional maintenance. For each activity, verify that it is accepted for the relevant pharmacist requirement, occurred within the correct license period, and can be supported by a completion record. A course registration or saved webinar link does not prove completion. Match the name, date, provider, credit designation, and amount shown on the record with what is entered in a renewal attestation. If credit appears in a tracking system, still make sure the activity is attributed to the right professional and period. Keep records accessible for an audit, including corrections when a provider report is missing. The practical sequence is to reconcile records before attesting, resolve gaps, and only then state that the requirement has been met. The North Dakota practice questions offer opportunities to apply status and documentation distinctions.

Worked example: Priya completed two eligible courses during the current renewal period, but only one completion certificate is in her records. She checks the provider and credit tracker for the missing course. If completion cannot be established, she does not count it in an attestation; she completes another qualifying activity within the permitted period if needed. Attendance from memory alone is not adequate proof.

Watch the distinction: Buying or attending a course is not the same as documented qualifying credit. The date, acceptance category, and evidence of completion must match the renewal claim.

Reference: [1]; [2]

15. Competence after a practice change

A license establishes the legal professional role, but safe practice also depends on current competence for the service assigned. Moving from routine community dispensing into sterile preparation introduces different risks: contamination, ingredient verification, environmental controls, technique, calculations, and release checks. A pharmacist should identify the tasks in the new setting, complete appropriate training, demonstrate the required skills, and work within the site’s validated procedures. Supervision or restricted assignments may be sensible until competence is demonstrated. This is a professional judgment question as well as a staffing question. The person must be legally authorized, the facility must be equipped and permitted for the activity, and the specific preparation must meet its quality requirements. Past experience is useful evidence, but skills can decay and standards can change during a long absence.

Worked example: A licensed community pharmacist is assigned to verify sterile preparations after several years away from that work. The manager checks the pharmacist’s current training and observed technique before assigning independent verification. Until competence is demonstrated, another qualified pharmacist handles the release decision. The active license remains necessary, but it does not by itself establish current sterile preparation skill.

Watch the distinction: Holding a pharmacist license does not prove readiness for every specialty task. Competence should be demonstrated for the actual process, equipment, and risks before independent responsibility is assigned.

Reference: [1]

16. Professional judgment and refusal

A pharmacist’s dispensing decision combines legal validity with clinical appropriateness. Verify the order and prescriber, review the patient’s profile and stated use, and examine any discrepancy that could cause harm. Options include dispensing, seeking clarification, delaying, or declining; choose according to the unresolved risk and the available authority. If an unusual dose may be intentional, gather evidence from the regimen, diagnosis, prior fills, and prescriber rather than assuming either error or safety. When the prescriber cannot be reached, assess whether any lawful emergency route applies, but do not invent an authorization to make a substantive dose change. Explain the delay plainly to the patient, seek timely resolution, and record the concern and contacts. A refusal should address the patient’s immediate need through a safe next step, such as contacting another authorized clinician.

Worked example: A patient’s prior order was 5 mg once daily; a new order says 50 mg once daily with no explanation. The prescriber’s office is closed and the patient has no documentation of a planned increase. The pharmacist holds the new fill, records the tenfold discrepancy and contact attempt, explains the need for clarification, and helps the patient reach an authorized source of care.

Watch the distinction: A complete prescription can still be clinically unsafe. Nor may the pharmacist silently substitute the old dose; that would create a different order without adequate authority.

Reference: [1]

17. Meaningful patient counseling

Effective counseling gives the patient enough information to use a medicine safely, not just a recitation of label words. Start with the intended regimen and confirm that the patient understands the dose, timing, route, and purpose. Select risks that matter for this drug and this person, including a warning sign that should prompt action. Discuss practical precautions, relevant monitoring, and what to do after a missed dose when that advice can be supported for the specific medicine. Ask a question that reveals understanding, such as how the patient plans to take the first dose. An interpreter or accessible format may be needed to make the discussion usable. The pharmacist should distinguish a routine effect from a serious symptom without offering unsupported reassurance. Document material concerns and any intervention that changed the dispensing decision.

Worked example: A patient starting a sedating medicine asks whether evening dosing is acceptable. The pharmacist confirms the prescribed timing and explains that drowsiness may impair driving or other hazardous tasks until the patient knows the effect. The patient is told to seek prompt help for marked difficulty staying awake or breathing problems. The pharmacist checks the patient’s understanding of the first dose and safety plan.

Watch the distinction: Answering only the question asked can leave a predictable safety risk unaddressed. Counseling should be selective and patient-specific, but it must cover the key use and response information.

Reference: [1]

18. Counseling through a caregiver

A caregiver may help a patient manage medication, but the pharmacist should establish why the caregiver is receiving information and how much is needed. Determine the patient’s expressed preference or other applicable authority, confirm the caregiver’s role when reasonable, and communicate instructions necessary for safe use. Privacy is a limit on unrelated disclosures, not a reason to withhold essential directions from an appropriately involved caregiver. Use a private setting if sensitive information might be overheard. If the patient lacks capacity, apply the relevant representative rules and document the basis for communication. The counseling itself should still be usable: identify the dose, administration method, major precautions, and problems that require help. A caregiver’s presence does not remove the need to address the patient directly when the patient can participate.

Worked example: Amira asks her spouse to collect a new prescription and hear the directions. The pharmacist confirms the request, then explains the prescribed dose, timing, and a relevant warning to the spouse. The pharmacist does not discuss Amira’s unrelated medication history at the counter. The record reflects the counseling recipient and any significant question, while Amira can still receive direct counseling later if needed.

Watch the distinction: A spouse’s relationship alone is not a blanket release of the patient’s record. Share what the caregiver needs for the medication task under the applicable privacy rules.

Reference: [1]

19. Recording counseling and interventions

A useful counseling record distinguishes an offer, an actual discussion, a refusal, and a clinical intervention. Include the date, relevant medicine or order, the issue raised, the person involved, and the outcome. If the patient declines, record that fact without claiming a conversation occurred. If a prescriber clarifies a changed dose, preserve both the original concern and the authorized resolution so a later reviewer can understand why dispensing proceeded. Avoid vague entries such as “counseled” when a specific risk or instruction mattered to safety. Documentation should be contemporaneous and attributable to the person who made it; corrections should leave the earlier entry traceable. The record helps future care, quality review, and accountability. It also prevents another pharmacist from repeating a resolved question or relying on an assumed answer.

Worked example: A patient receives a prescription with a newly increased dose. The pharmacist offers to discuss the change, but the patient says they understand it and decline. The pharmacist records the offer, refusal, date, and dose change; the note does not say the new regimen was explained. If an unresolved safety concern remains, the refusal does not eliminate the pharmacist’s duty to assess it.

Watch the distinction: A counseling refusal is not proof that counseling occurred, and a checked box cannot explain a material clinical decision. Record the actual sequence and resolution.

Reference: [1]

20. Allergy assessment

An allergy entry is a starting signal, not a complete clinical history. Clarify the drug, reaction, timing, severity, treatment, and whether the patient tolerated related medicines later. Nausea alone often describes an adverse effect or intolerance, while hives, swelling, or breathing difficulty may suggest hypersensitivity; the history and context still matter. Compare the proposed drug with the implicated medicine and the nature of the reaction before resolving an alert. A vague family history should not be silently converted into the patient’s own allergy. If the reaction is uncertain and the potential harm is serious, seek additional information or an alternative plan before dispensing. Update the profile with the patient’s own words and the pharmacist’s assessment, keeping uncertainty visible. Better classification prevents both avoidable exposure and unnecessary loss of useful treatment options.

Worked example: The profile says “penicillin allergy: nausea,” and an amoxicillin order arrives. The pharmacist asks whether the patient had a rash, swelling, breathing trouble, or treatment for the event. The patient reports isolated stomach upset years ago and no other symptoms. The pharmacist documents that history as likely intolerance, assesses the current prescription and patient factors, and resolves the alert with a recorded rationale.

Watch the distinction: An allergy label should not be ignored or accepted uncritically. Calling nausea anaphylaxis overstates the history, while deleting the entry without recording the actual reaction loses useful information.

Reference: [1]

21. Interaction assessment

An interaction alert is a reason to investigate, not a verdict. First identify the mechanism: one drug may change the other's concentration, or both may produce the same harmful effect. Then assess the likely consequence, the doses, when each drug was started, and whether exposure will overlap. Patient factors can change the decision. Reduced kidney function, for example, may prolong exposure to a drug whose clearance is already impaired. Check the medication history for prior tolerance, but remember that a new dose or change in organ function can make that history less reassuring. Possible responses include an alternative drug, a dose change authorized by the prescriber, targeted monitoring, or delaying dispensing. Record the facts and agreed plan so the next pharmacist can distinguish a resolved risk from an ignored alert.

Worked example: A patient with reduced kidney function takes a maintenance drug cleared partly by the kidneys. A newly prescribed drug may raise its concentration. The pharmacist confirms the current dose, kidney information, and expected overlap, then contacts the prescriber. They agree on an alternative that avoids the interaction. The pharmacist records the discussion and dispenses the alternative only after receiving a valid order.

Watch the distinction: A familiar alert is easy to dismiss when the patient has taken one drug for years. The new drug and changed kidney function make the current combination a new clinical question.

22. Therapeutic duplication

Two medicines with similar effects may represent an error, a planned switch, or a deliberate combination. Compare active ingredients, drug classes, routes, scheduled use, and intended treatment periods. Do not infer duplication solely from similar names: some regimens intentionally pair distinct inhaled drug classes. Conversely, different brand names can conceal the same active ingredient. Establish whether the older order remains active and whether either clinic knows about the other order. If one product replaces another, obtain the authorized plan, update the profile, and tell the patient which inhaler to stop and which to start. If both are intended, document the rationale and assess combined risks. The dispensing decision should reflect the actual regimen, since an outdated profile can generate repeated alerts and make later care less safe.

Worked example: Clinic A sends a new inhaler prescription while Clinic B's similar inhaler remains on the patient's profile. The pharmacist asks the patient what is being used and contacts Clinic A. Clinic A confirms the new inhaler replaces the old one. The pharmacist records that instruction, marks the older therapy discontinued in the profile, and explains the switch before dispensing.

Watch the distinction: Two active prescriptions do not prove that both should be used. Prescription status can lag behind a treatment change, especially when separate clinics manage the same patient.

23. Contraindications and patient factors

A contraindication links a drug to a patient characteristic that makes its use unsafe or generally inappropriate. A warning is different: it may call for dose selection, monitoring, or a risk-benefit decision. Read the alert's reason, then verify the underlying patient fact. Pregnancy status, kidney or liver function, age, diagnoses, and prior reactions may be missing or outdated in the profile. Ask whether the risk applies to this formulation, route, dose, and duration. A topical product and a systemic product may create different exposure, for instance. When a documented condition creates a material risk, pause dispensing and clarify the prescriber's intent. Record what was verified and how the issue was resolved. Do not silently change the regimen, since clinical concern alone does not create prescribing authority.

Worked example: A patient profile lists a serious chronic condition that could increase the risk of a newly ordered medicine. The pharmacist confirms the diagnosis is current and checks the proposed dose and route. After discussing the concern, the prescriber sends an order for a different medicine. The pharmacist records the change and dispenses against the new order.

Watch the distinction: An alert is not automatically correct, but neither is an old chart entry automatically obsolete. Verify the patient fact before accepting or dismissing the warning.

24. Resolving a utilization-review alert

A defensible override answers three questions: what risk did the system identify, what evidence changes its significance here, and what plan controls the remaining risk? Review the patient's medicines and relevant clinical facts rather than relying on the alert label. A prescriber may have intentionally lowered a dose and arranged monitoring, but that plan must be confirmed and suitable for the patient. Check whether the monitoring can actually occur and whether the patient understands warning symptoms. Document the prescriber contact, adjusted order, monitoring plan, and reason for dispensing. If the evidence is incomplete, leave the alert unresolved while seeking clarification. A computer's acknowledgment button records that someone saw a warning; it does not establish that the prescription was safe or legally authorized.

Worked example: An interaction alert appears for a new drug and a chronic medicine. The pharmacist confirms that the prescriber intentionally reduced the chronic medicine's dose and arranged a follow-up test. The patient understands the revised directions and knows when the test is due. The pharmacist records those facts and the prescriber's confirmation before dispensing.

Watch the distinction: An override note saying only 'prescriber aware' omits the decision's basis. Record the actual dose change, monitoring arrangement, and patient instructions so the resolution can be assessed later.

25. Initiating therapy under authority

Before starting a medicine without an individual prescriber order, identify the authority that permits the pharmacist to act. North Dakota describes limited prescriptive authority for specified services under Board-approved protocols; that authority has boundaries. Read the applicable rule and protocol for the covered product, patient eligibility, screening, required training, documentation, and communication. Confirm that the particular pharmacist and pharmacy meet those conditions. A product's nonprescription availability is a separate route and does not expand prescription authority. If the requested treatment falls outside the authorization, assess the patient's need and direct them to a clinician who can evaluate it. The safe decision sequence is authority first, eligibility second, clinical assessment third, and documentation after the authorized action.

Worked example: A patient asks a North Dakota pharmacist to prescribe a treatment the pharmacy often supplies. The pharmacist identifies the proposed medicine and checks whether a current authorization covers it and this patient. The requested treatment is outside that scope, so the pharmacist does not issue a prescription. They explain the limit and help the patient reach an appropriate prescriber.

Watch the distinction: Experience dispensing a medicine does not grant authority to prescribe it. The legal basis must cover the specific service and patient before clinical familiarity matters.

Reference: [1]; [4]

26. Collaborative practice agreements

A collaborative agreement delegates defined actions within a defined clinical relationship. Read it as a set of conditions: who signed it, which patients are enrolled, which conditions and medicines it covers, what the pharmacist may change, and when the prescriber must be contacted. Check documentation, monitoring, and communication duties before acting. An agreement authorizing dose adjustments for enrolled patients does not authorize starting a different medicine for any person who walks in. Likewise, a clinically reasonable change can still exceed the agreement. State borders matter because authority is jurisdiction specific; a South Dakota MPJE study guide can help compare issues, but North Dakota authority governs the North Dakota action. When a case falls outside the agreement, seek a separate valid order.

Worked example: An agreement permits dose adjustments for enrolled patients with a named condition. A walk-in patient has that condition and asks the pharmacist to change a dose, but is not enrolled. The condition matches; the patient eligibility requirement does not. The pharmacist does not adjust under the agreement and contacts the patient's prescriber to arrange an authorized plan.

Watch the distinction: Matching the disease is only one condition. An agreement can also limit eligible patients, medicines, actions, and required follow-up; failing any applicable condition defeats that route.

27. Modifying or discontinuing therapy

Correcting a dispensing detail and changing therapy are different acts. Fixing a transcription error makes the pharmacy record match an already authorized order. Halving a prescribed dose changes the regimen and needs prescriber authorization or another valid source of pharmacist authority. When a patient reports an adverse effect, first assess urgency and whether immediate medical evaluation is needed. Review the medicine, dose, timing, other drugs, and symptom pattern. Explain safety precautions that fit the facts, then obtain an authorized treatment decision rather than writing a new direction by implication. If a collaborative agreement or specific protocol covers the patient and change, follow its limits and record the action. Otherwise, contact the prescriber and document the response, including any new order and the instructions given to the patient.

Worked example: A patient taking one tablet twice daily reports dizziness and asks to take half a tablet instead. The pharmacist assesses the symptom and confirms the current order. No applicable agreement authorizes a dose change, so the pharmacist contacts the prescriber. The prescriber issues revised directions, which the pharmacist records and explains; the patient's request alone did not change the order.

Watch the distinction: Counseling about a possible side effect does not authorize a new regimen. Separate immediate safety advice from the decision to modify or discontinue prescribed therapy.

28. Immunization services

An immunization encounter has both an authority check and a clinical screening check. Confirm that the pharmacist may provide the particular vaccine under the applicable North Dakota authority and that the patient meets the protocol's criteria. Review vaccine history, relevant illness, prior reactions, and component allergies. Obtain appropriate consent and prepare for a reaction before administration. Afterward, record the product, dose, route, site, date, administrator, and other required details, then complete any required communication or registry reporting. A valid authority or order establishes who may provide the service; it does not erase a patient-specific contraindication. If screening uncovers a severe prior reaction to a component, pause, clarify what happened, and choose an appropriate referral or alternative pathway rather than proceeding automatically.

Worked example: A patient requests a vaccine that the pharmacy provides under its applicable authority. During screening, the patient reports a severe reaction to a component in an earlier dose. The pharmacist stops preparation, clarifies the reaction and product involved, and follows the service protocol for referral or further assessment. Consent and product availability do not resolve that safety concern.

Watch the distinction: Treating eligibility as a single yes-or-no check misses two separate questions. The pharmacist needs authority to administer, and the patient must be clinically suitable for that product.

Reference: [1]; [4]

29. Testing and clinical services

A point-of-care test produces information; the authority to act on that information must be identified separately. Confirm that the pharmacy and staff may perform the test, that the test is appropriate for the patient, and that collection and quality procedures are followed. Interpret the result in light of symptoms, timing, and the test's limits. A positive result may support referral or treatment under a specifically authorized protocol, but it does not grant unrestricted diagnostic or prescribing power. A negative result may also require follow-up when symptoms or exposure make the result unreliable. Document the test, result, patient communication, and disposition. For North Dakota services, the Board's listed laws and rules identify relevant regulatory areas, while the particular service authority controls the next step.

Worked example: A pharmacist performs an authorized point-of-care test, and the result is positive. The service protocol allows testing and referral but gives no treatment authority for this condition. The pharmacist explains the result and its limits, documents it, and directs the patient to an appropriate clinician. The positive result does not itself become a prescription.

Watch the distinction: Permission to run a test is not permission to prescribe every possible treatment. Identify the separate authority for diagnosis, treatment, and follow-up.

Reference: [1]

30. Emergency continuity of care

An urgent refill request calls for two parallel assessments: the risk of interruption and the legal authority to supply medication. Confirm the patient's identity, the established regimen, last dispensing, remaining authorization, and any changes in treatment. Consider how quickly missed doses may harm the patient and whether the medicine itself creates risks if supplied without fresh evaluation. If a lawful emergency route applies, use only the supply and process it permits, then document the basis, quantity, and follow-up. If it does not apply, help the patient reach an on-call prescriber, urgent care, or another appropriate service. An empty bottle and a closed office establish a need for help, but they do not alone create dispensing authority. Clear documentation lets the next pharmacist see what was provided and why.

Worked example: A patient runs out of a maintenance medicine after the prescriber's office closes. The pharmacist verifies the patient, recent fill, and established directions, then checks the applicable emergency authority. It permits a limited supply in these circumstances. The pharmacist provides only that lawful amount, records the reason and quantity, and tells the patient to contact the prescriber when the office opens.

Watch the distinction: A familiar medication is not automatically eligible for an emergency supply. The pharmacist must confirm both the clinical need and the legal route for dispensing it.

31. Essential prescription information

A dispensable prescription must identify the patient, an authorized prescriber, the medicine and intended use, and the order's date and authentication in the form required for that order. Strength, dosage form, quantity, and directions must be clear enough to select the product and produce an accurate label. Review all elements together: a signature cannot cure missing directions, and a complete label cannot cure an invalid source order. If a field is ambiguous, determine whether it is a transcription issue or a clinical decision requiring the prescriber. Obtain clarification through an authorized channel and preserve who supplied it, when, and what changed. For controlled substances, also check schedule-specific elements and restrictions. The pharmacist's final review should compare the clarified order, selected product, and patient-facing instructions.

Worked example: A signed order specifies a drug, strength, and quantity but says only 'use as directed.' No separate directions are available to the pharmacy. The pharmacist contacts the prescriber, receives a specific schedule, and records the source and time of clarification. The label is prepared from the clarified order, then checked against the selected product before release.

Watch the distinction: A signed order is not automatically ready to fill. If the directions cannot guide use or labeling, resolve them through an authorized source before dispensing.

32. Prescriber authority

A clinician's license establishes a professional role, but prescribing authority can depend on drug class, practice scope, patient relationship, setting, and additional registration. Confirm the prescriber's identity and credentials, then ask whether this particular order falls within that authority. Controlled substances add federal registration and schedule considerations, along with any applicable state conditions. Do not infer authority merely because a name appears in a directory or a prior order was accepted. If an agent transmits an order, distinguish the agent's communication role from the prescriber's decision and authorization. Resolve uncertainty before dispensing, documenting the verification source and outcome. A pharmacy may decline an invalid order while helping the patient obtain a lawful replacement from an appropriately authorized prescriber.

Worked example: A prescription arrives from a licensed clinician for a drug class the pharmacist has not seen that clinician prescribe. The pharmacist verifies the clinician's professional scope and any required controlled-substance registration for the drug. If the authority is confirmed, dispensing may proceed after the remaining checks. If it is absent, the pharmacist seeks a new order from an authorized prescriber.

Watch the distinction: A valid professional license does not prove authority for every drug. Match the prescriber's scope and required registrations to the specific prescription.

Reference: [3]

33. Prescription communication channels

The communication channel affects how an order is authenticated and what record the pharmacy must retain. A written order, a directly received oral order, an electronic order, and a fax are not interchangeable for every medicine. Identify the drug's controlled-substance schedule first, then evaluate whether that channel is permitted for the intended dispensing. Confirm who may communicate the order and whether an agent is transmitting a prescriber's authorized instruction rather than making a clinical decision. For a fax, determine whether it is the operative prescription in that circumstance or only advance information pending another valid form. Record any lawful clarification without disguising a channel problem as a transcription correction. The final question is whether the pharmacy has an authorized prescription in a permissible form before it releases the medicine.

Worked example: A faxed controlled-substance order reaches the pharmacy. The pharmacist identifies its schedule and intended use, then checks whether a fax can serve as the dispensing prescription in those circumstances. If it cannot, the pharmacy waits for a permitted form rather than treating the fax as sufficient. The patient is told what is needed and the prescriber is contacted.

Watch the distinction: A legible fax with a prescriber's signature is not necessarily the operative prescription. Channel restrictions can depend on the drug's schedule and the circumstances.

Reference: [3]

34. Schedule-specific prescription limits

Controlled-substance scheduling changes the rules for prescribing, refills, communication, and records. Classify the exact product before applying a rule: similar drug names, combinations, and formulations may have different legal treatment. For Schedule II, federal law does not permit refills. A later dispensing therefore needs another lawful basis, such as a separate valid prescription, rather than an unused refill notation on the original. Other schedules have their own refill and validity limits; apply the controlling federal and North Dakota requirements together. Also check whether an order's form and the prescriber's authority fit the schedule. The DEA Diversion Control Division provides federal scheduling and registration resources, while the dispensing decision still requires the applicable rule for the specific transaction.

Worked example: A valid Schedule II prescription directs 30 tablets and lists three refills. The pharmacist may assess the initial 30-tablet dispensing, but cannot use the three refill entries: Schedule II refills are prohibited. Once that authorized dispensing is complete, another supply requires separate lawful authority. The pharmacist documents the issue and seeks a new prescription when needed.

Watch the distinction: A prescriber's written refill number does not override a schedule restriction. Read the drug's schedule before using any refill field in the pharmacy system.

Reference: [3]

35. Emergency Schedule II orders

Federal law permits an oral Schedule II prescription in a narrowly defined emergency. The pharmacist must determine that the situation meets the emergency criteria, receive the order directly through an authorized communication, and limit the quantity to what is needed during the emergency period. Record the required prescription details and the reason for using the emergency route. The prescriber must provide the required follow-up prescription within the legally specified period, and the pharmacy must track whether it arrives and act if it does not. An urgent request alone does not establish the exception; the inability to use the ordinary written or electronic route and the need for immediate treatment matter. State requirements may add conditions, so apply both federal and North Dakota law before dispensing.

Worked example: A prescriber calls with an urgent Schedule II order. The pharmacist establishes why immediate treatment is needed and why an ordinary prescription cannot be supplied in time. After confirming the emergency exception, the pharmacist records the oral order and dispenses only the amount needed for that period. The pharmacy tracks the required follow-up prescription and responds if it is not received.

Watch the distinction: A phone call from a legitimate prescriber is not enough for an emergency Schedule II fill. The emergency conditions, limited quantity, records, and follow-up all matter.

Reference: [3]

36. Refills and prescription age

Refill authorization and prescription validity are separate limits. A profile may show one refill remaining because the prescriber allowed it, yet the prescription may be too old to dispense under the applicable law. Start with the drug and its schedule, then identify the order date, prior dispensings, authorized refills, and any expiration rule that applies. The usable authorization is constrained by both the remaining refill count and the permitted time window. A pharmacy system's displayed balance is an accounting aid, not a legal extension. If the prescription has expired, seek a new authorized order; do not relabel the old refill as a fresh prescription. If the order remains valid, assess the usual clinical and dispensing checks before supplying it.

Worked example: A patient's profile shows one refill left on an old prescription. The pharmacist checks the drug's schedule and the order date against the applicable validity period. The order has passed that period, so the unused refill cannot be dispensed. The pharmacist contacts the prescriber for a new order and explains why the computer's remaining-refill display did not settle the question.

Watch the distinction: A refill count answers how many repeats were authorized, not how long the order remains usable. Check both limits before dispensing.

37. Partial fills

A partial fill supplies less than the authorized quantity under the same prescription. It does not create a new refill or enlarge the original order. Record the quantity actually supplied, the balance, the date, and the reason for the partial fill. Before completing the balance, check the drug's schedule, the reason for partial dispensing, the applicable completion window, and whether the prescription remains otherwise valid. A patient's request, stock shortage, or clinical plan can lead to different controlled-substance rules, so do not apply one completion rule to every case. Reconcile the running balance after each supply and ensure the label reflects what the patient received. If the permitted window closes, the unfilled balance may require a new lawful prescription.

Worked example: An order is for 30 tablets, but only 18 are supplied because stock is short. The recorded balance is 30 minus 18, or 12 tablets. Before supplying those 12, the pharmacist checks the drug's schedule and the completion rule for a stock-shortage partial fill. The balance is supplied only if that rule still permits completion, and both transactions remain linked to the original order.

Watch the distinction: The remaining 12 tablets are not a refill. They are an unfilled part of the original 30-tablet order, subject to its own completion conditions.

Reference: [3]

38. Prescription transfers

A transfer moves usable prescription authority between pharmacies; it does not duplicate it. Identify the drug, schedule, original order, remaining refills or unfilled quantity, and whether the applicable rules permit that type of transfer. The sending and receiving pharmacies must exchange information through an authorized process and maintain records that show where the active authority resides. For controlled substances, transfer rules can differ by schedule and by whether the prescription was previously dispensed, so distinguish an original electronic order from a refill transfer. Verify the prescriber and patient information, previous dispensing, and what remains available. Once transferred, the pharmacies must avoid parallel filling against the same authorization. If transfer is unavailable, help the patient obtain a new lawful order rather than inventing a refill.

Worked example: A patient asks Pharmacy B to fill a controlled-substance prescription held by Pharmacy A. Pharmacy B identifies the schedule and whether the request concerns an original order or remaining refills. The pharmacists use the permitted transfer process, record the transaction, and confirm the balance. Pharmacy B dispenses only what remains legally available; Pharmacy A no longer treats the transferred authority as independently usable.

Watch the distinction: Copying prescription details into a second system does not create a second valid order. A lawful transfer must preserve one accountable dispensing history and remaining balance.

Reference: [3]

39. Changing an existing order

When an existing order needs correction, classify the change before acting. A transcription correction makes the pharmacy entry match the prescriber's actual order. Clarification resolves unclear wording through an authorized source. A different strength, dosage form, quantity, or direction may be a substantive change even when the daily amount appears equivalent. Check the drug's schedule and any limits on what a pharmacist may change. If prescriber authorization is required, obtain and record it before dispensing. Then calculate the new directions and quantity, and verify that the selected product delivers the intended dose. Preserving the original order and the change history matters because later reviewers must see which instruction was authorized. Do not let a shortage or insurance preference silently rewrite therapy.

Worked example: The order calls for one 20 mg tablet daily, but only 10 mg tablets are available. Two 10 mg tablets deliver 20 mg per day. The pharmacist checks whether the substitution is permitted or needs prescriber authorization, obtains that authorization when required, and records the change. For a hypothetical 30-day supply, the new quantity is 2 tablets per day times 30 days, or 60 tablets.

Watch the distinction: Equal milligrams do not automatically make a product change lawful. Strength, tablet count, directions, and quantity must all be authorized and recorded.

40. Corresponding responsibility

A pharmacist has an independent duty to assess whether a controlled-substance prescription was issued for a legitimate medical purpose in the usual course of professional practice. Complete fields and a valid-looking signature do not resolve contradictory facts. Examine the specific warning signs, such as identity conflicts, unexplained overlap, altered directions, or inconsistent prescriber information. Verify the facts through appropriate records and direct communication where needed; a monitoring record is one source of context, not a verdict about the patient. Document what was found, who was contacted, and why the concern was resolved or remained unresolved. If material doubts remain, delay or decline dispensing while addressing the patient's immediate needs appropriately. North Dakota MPJE practice questions can help rehearse this decision sequence.

Worked example: A controlled-substance order contains every required field, but the patient gives a different birth date from the pharmacy record and requests supply earlier than expected. The pharmacist verifies identity, reviews dispensing history, and contacts the prescriber about the timing. If the discrepancies are explained and the order is valid, dispensing can proceed with documentation. If they remain unresolved, the pharmacist does not dispense.

Watch the distinction: Corresponding responsibility is not satisfied by checking boxes or by assuming suspicious behavior. Investigate specific discrepancies and base the dispensing decision on resolved facts.

Reference: [3]

41. Generic substitution

A pharmacist first compares the prescribed product with the proposed generic at the level of active ingredient, strength, dosage form, and route. Evidence of therapeutic equivalence then matters: an FDA therapeutic equivalence rating can help establish that a generic is expected to have the same clinical effect when used as labeled. Similar names or membership in the same drug class do not establish equivalence. Next, check the prescription for a valid prescriber restriction and apply North Dakota’s substitution conditions, including any patient communication and record requirements. The dispensing record should identify the product actually supplied so later refills, recalls, and questions can be traced. If the products differ in ingredient or regimen, analyze a therapeutic change instead. A neighboring state’s approach, discussed in the Minnesota MPJE guide, does not determine the North Dakota rule.

Worked example: A prescription orders Brand A, 10 mg tablets, one daily for 30 days, with no substitution restriction. The pharmacist finds an eligible generic with the same active ingredient, strength, tablet form, and route, confirms therapeutic equivalence and North Dakota conditions, then records the generic actually dispensed. Thirty tablets provide 30 days at one tablet daily. A different ingredient in the same class would require separate authority.

Watch the distinction: A lower price does not make two medicines interchangeable. Generic substitution depends on the particular product’s equivalence and the applicable prescription and state conditions.

42. Therapeutic interchange

Changing from one active ingredient to another, or changing the regimen materially, is therapeutic interchange. It is a clinical change to the order even when both medicines treat the same condition. Start by identifying exactly what would change: ingredient, dose, formulation, route, frequency, or monitoring. Then identify a valid source of authority, such as prescriber approval or an applicable agreement or protocol that covers this patient and proposed action. Formulary preference, stock shortage, and insurance rejection explain why a change is considered; none independently authorizes it. Assess whether the replacement dose is clinically appropriate rather than assuming equal milligrams mean equal effect. Record the authorization, new directions, communication, and product dispensed. When authority is absent, keep the original order pending and seek an authorized decision.

Worked example: A plan prefers Drug B over prescribed Drug A, and both are in the same therapeutic class. The pharmacist finds no interchange agreement covering this patient, so asks the prescriber to approve Drug B and its specific regimen. After approval, the pharmacy records the new order and counsels the patient. The plan’s preference alone would leave Drug A as the operative prescription.

Watch the distinction: Calling a change a ‘formulary substitution’ does not turn it into generic substitution. A different active ingredient needs its own clinical assessment and lawful authorization.

43. Labels and packaging

A dispensing label translates the authorized order into instructions for this patient and must agree with the product in the container. Compare the final order, stock bottle, quantity, patient identity, and generated label before release. Directions should communicate dose, route, frequency, and relevant timing clearly; warnings should match the medicine and patient. Include the identifying details required by applicable law and maintain a record of what was supplied. Packaging is a separate safety decision: select a suitable container that protects the product and meets applicable child resistance rules or a valid exception. A correct container cannot repair a wrong label, and a correct label cannot repair a wrong product. Any clarification should flow into the prescription record and final verification, not remain only in a phone note.

Worked example: The clarified order is two 5 mg tablets by mouth daily for 30 days, so the intended quantity is 2 × 30 = 60 tablets. A technician prepares a suitable child resistant container but prints ‘take one daily’ and quantity 30. The pharmacist corrects both fields, confirms 60 tablets of the ordered product, and checks the revised label before release.

Watch the distinction: An accurate stock count and safe container do not make the dispense correct. The patient may follow the label, so directions must match the authorized regimen.

44. Prescription monitoring information

North Dakota’s Prescription Drug Monitoring Program provides dispensing history that can inform a controlled substance decision. First satisfy any applicable access or query duty. Then interpret the entries: identify the drug, dates, quantity, reported days’ supply, prescribers, and pharmacies, while allowing for reporting delays or corrections. Compare the history with the current order and the patient’s explanation. An overlap may reflect a dose change, lost medication, coordinated care, or misuse; the record alone does not establish which. Resolve material discrepancies through appropriate patient and prescriber communication, apply independent professional judgment, and document the basis for dispensing or withholding. Access to sensitive monitoring data should remain limited to authorized purposes, and a query should never replace review of the prescription itself.

Worked example: A patient requests 30 tablets of a controlled medicine today. The monitoring record shows 30 tablets dispensed 10 days ago with a stated 30 day supply. On those reported directions, 20 days of supply would remain, but a documented dose change could alter that estimate. The pharmacist verifies the prior directions and current plan, contacts the prescriber if needed, and records the resolution before deciding.

Watch the distinction: A recent monitoring entry is a warning sign, not proof of diversion. Calculate the apparent overlap, check the underlying regimen, and resolve conflicting facts.

Reference: [1]

45. Errors and recalls

A misfill and a product recall require linked but distinct responses. For an error, determine what the patient actually received, whether any doses were taken, the likely clinical risk, and the immediate care or replacement needed. For a recall, identify the affected product and lot, quarantine remaining stock, and trace dispensing records to patients who may have received it. Follow the recall’s stated scope and urgency when arranging notification, return, or disposal. Preserve the original transaction and record corrections transparently, including contacts, advice, replacements, and unresolved outreach. Investigate the process that allowed the error or recalled product to reach patients, then verify that a corrective step works. Patient protection comes first; closing an inventory discrepancy without contacting affected patients would leave the main risk unresolved.

Worked example: A recalled lot appears in three patient records. Review also shows that one of those patients received 20 mg tablets instead of ordered 10 mg tablets. The pharmacy quarantines remaining lot stock, contacts all three patients under the recall plan, and urgently assesses the wrong strength with that patient and the prescriber. It documents both investigations and verifies corrected stock and records.

Watch the distinction: Treating the wrong strength as merely part of the recall can miss a separate overdose risk. Each event needs its own patient assessment and documented resolution.

46. Pharmacy permits

A pharmacist’s personal license and a facility’s authority to operate answer different questions. Before a North Dakota site begins pharmacy activity, identify the legal operator, physical location, proposed services, responsible pharmacist, and applicable facility permit. A change in services may also alter permit conditions or require notice. The North Dakota Board of Pharmacy provides the state’s pharmacy licensing and regulatory entry point, but the decisive fact in a scenario is whether the specific site has the required authority for the proposed activity. Do not infer permission from a lease, stocked shelves, a pharmacist’s license, or an application receipt. Confirm the permit status and any preopening conditions before accepting prescriptions or dispensing. Keep the facility’s records and responsible personnel aligned with the permitted operation.

Worked example: A company leases a North Dakota storefront, installs dispensing software, and hires a licensed pharmacist. Its facility permit is still pending. The pharmacist can help prepare the site, but the company cannot treat those preparations as authorization to dispense there. The opening decision waits for the applicable permit and conditions to be satisfied; the individual pharmacist’s license does not supply the missing facility authority.

Watch the distinction: A licensed pharmacist does not automatically license the premises. Personnel credentials, controlled substance registrations, and the pharmacy permit each authorize different parts of the operation.

Reference: [1]

47. Nonresident pharmacy obligations

Shipping a prescription across a state line brings the destination state into the compliance analysis. For an out of state pharmacy serving North Dakota residents, separate the home state license from any North Dakota nonresident facility requirements, applicable pharmacist authority, controlled substance permissions, and patient service obligations. The dispensing site still performs its own order review, product verification, labeling, and recordkeeping; shipping does not erase those duties. Check how the patient can obtain counseling, report an error, or reach the pharmacy, and how delivery is documented and protected against damage or temperature exposure. Determine the destination requirements before the first shipment, including whether a change of ownership or location affects registration. The question is where the patient receives pharmacy service, not merely where the dispensing shelves stand.

Worked example: A Minnesota mail pharmacy receives its first order for a North Dakota resident. It has an active Minnesota license and a validated prescription, but has not established its North Dakota nonresident status. The pharmacy verifies the destination state requirements before shipping, then confirms labeling, counseling access, and delivery controls. A valid home state license alone does not answer whether this shipment is authorized.

Watch the distinction: Mailing from another state does not place the transaction outside North Dakota’s regulatory reach. Destination state obligations can apply even when no North Dakota storefront exists.

48. Ownership and permit changes

A pharmacy permit is tied to a defined operator and operation, so a sale, relocation, or material service change needs a separate permit analysis. Identify what is changing: legal ownership, controlling entity, address, responsible pharmacist, or permitted activities. Then determine whether North Dakota requires a new application, amendment, notice, inspection, or other action before the changed operation begins. Keep the old and new operators’ prescription records, controlled stock, patient information, and outstanding obligations accounted for during the transition. A buyer should not assume that acquiring inventory also conveys the seller’s permission to operate. Likewise, moving shelves across town is not merely a change in mailing address if the licensed location changes. Document the effective transition so each transaction can be attributed to the proper entity and site.

Worked example: A buyer closes on a North Dakota pharmacy on Monday and plans to dispense Tuesday under the seller’s posted permit. The buyer first identifies the new legal operator, confirms the required Board permit action and effective date, and arranges lawful transfer of stock and records. Until the buyer’s operation is authorized, the seller’s permit cannot simply be treated as the buyer’s.

Watch the distinction: A permit number on the wall does not prove that the current owner and location are covered. Compare the permit with the entity and site actually operating.

49. Lawful drug procurement

Drug procurement is a chain of custody problem as well as a price decision. Verify that the seller is an authorized trading partner for the products offered, that the invoice and required transaction information identify what was purchased, and that packaging and product identifiers are consistent. On receipt, compare the shipment with the order, note damage or discrepancies, and segregate suspect product while authenticity is investigated. Preserve records that let the pharmacy trace a product backward to its source and forward to patients if a recall occurs. Controlled medicines add registration and ordering requirements. A discount cannot compensate for an unverifiable source, missing traceability records, or evidence of tampering. Release to dispensing inventory only after the pharmacy can support the product’s identity and lawful acquisition.

Worked example: A supplier offers 100 bottles at a steep discount but cannot identify the authorized distributor or provide acceptable transaction documentation. The pharmacy holds the offer, verifies the supplier’s status, and requests the missing records. If those facts remain unresolved, it does not purchase or dispense the stock. The attractive unit price does not establish product authenticity.

Watch the distinction: An ordinary invoice may show a price without establishing lawful source or traceability. Check supplier authority and product documentation before putting stock into dispensing inventory.

50. Storage and temperature excursions

Storage decisions begin with each product’s labeled conditions, not a single rule for every refrigerator item. Monitoring should reveal the temperature reached, when the excursion began, and how long products were exposed. When an excursion is found, restore proper conditions and quarantine affected stock with clear identification so it cannot be dispensed accidentally. Reconstruct the exposure from reliable logs and equipment history, then seek product specific stability information from the manufacturer or another authoritative source. Assess each lot and dosage form separately; a brief deviation that one product tolerates may damage another. Record the evidence, decision maker, release or disposal decision, and preventive equipment repair. A return to normal temperature does not reverse any degradation that occurred during the excursion.

Worked example: Assume a product’s labeled upper storage limit is 8 °C. A logger shows 11 °C for six hours overnight, an excursion of 11 − 8 = 3 °C above that limit. Staff quarantine the affected lots and check product specific stability for six hours at that temperature. The arithmetic identifies exposure; it cannot establish that the medicine remains usable.

Watch the distinction: A refrigerator reading within range now says nothing about an overnight excursion. Reconstruct duration and affected lots before deciding whether to release stock.

51. Physical and electronic security

Security controls should match what each worker must do. Physical controls limit access to drug stock, especially controlled medicines, while system permissions limit access to patient records, prescription changes, inventory adjustments, and administrator functions. Give users individual credentials, remove access when duties change or employment ends, and retain logs that attribute sensitive actions to a person and time. Shared logins make investigations and accountability difficult. Review unusual inventory adjustments, overrides, and access outside normal work patterns, but interpret a log entry in context before concluding misconduct. If access is compromised, secure the account and stock, preserve evidence, assess affected transactions, and correct the underlying permission failure. A locked door alone cannot protect records if an active remote account still has broad privileges.

Worked example: A technician left last week, but their account can still adjust controlled stock. The pharmacy disables it immediately and reviews adjustments since the departure date. If the log shows two entries under that account, it investigates who made them and reconciles the related inventory rather than attributing them automatically to the former employee.

Watch the distinction: Deleting an account without reviewing its recent activity can hide an unresolved stock or record problem. Preserve the audit trail while removing access.

52. Controlled-substance registration

Controlled substance authority attaches to the registrant and activity at the relevant location. Before ordering, storing, dispensing, or moving controlled stock, identify the legal entity, physical site, drug schedules, and activity involved. Check the applicable federal registration through the DEA Diversion Control Division and any required North Dakota authority. A pharmacist’s professional license, the pharmacy permit, and controlled substance registration serve different purposes; one does not substitute for another. A second site may need its own authority even when the owner and pharmacist are the same. If stock moves between locations, analyze the transaction as a lawful transfer with the required records rather than an informal shelf move. Match each order and inventory record to the site actually receiving and handling the drugs.

Worked example: A company opens a second North Dakota pharmacy and proposes moving controlled stock from Site A before Site B begins dispensing. It confirms Site B’s facility and controlled substance authority, then uses the required transfer and receipt records for the movement. Site A’s registrations establish its own authority, not automatically Site B’s authority to possess or dispense the stock.

Watch the distinction: Common ownership does not make two addresses one registered location. Check the legal entity, site, activity, and schedule before moving controlled medicines.

Reference: [1]; [3]

53. Controlled-substance ordering and inventory

A controlled substance inventory should connect each acquisition and disposition to a defensible balance. Start with the prior count, add documented receipts and lawful returns to stock, then subtract dispensing, transfers, waste, and other recorded dispositions. Compare that expected balance with a physical count under the applicable inventory rules. Schedule and transaction type determine which ordering forms or electronic processes and records apply; an invoice by itself may not satisfy every requirement. Investigate discrepancies by checking dates, package sizes, reversals, unposted prescriptions, returns, and counting mistakes. Preserve the original entries and document any correction rather than forcing the system balance to match the shelf. If facts indicate theft or significant loss, move to the reporting analysis as well as correcting inventory.

Worked example: The ledger expects 42 tablets, but a physical count finds 39. The difference is 42 − 39 = 3 tablets short. Review finds a three tablet dispensing transaction that was verified but never posted. The pharmacy validates the patient record, posts an attributed correction, and recounts 39. If that evidence were absent, the shortage would remain under investigation rather than becoming an unexplained adjustment.

Watch the distinction: Changing the ledger from 42 to 39 without a supported transaction conceals the cause. Reconcile receipts and dispositions, then preserve who corrected what.

Reference: [3]

54. Losses, returns, and disposal

Every reduction in controlled stock needs a reason, but different reasons use different pathways. A documented patient dispense, authorized return, witnessed waste, destruction, or transfer is not the same as an unexplained disappearance. First secure remaining stock and reconstruct the movement through orders, delivery records, inventory, dispensing, returns, and access logs. If the facts indicate theft or significant loss, follow the applicable federal and North Dakota reporting duties promptly; significance depends on the circumstances, not merely a fixed quantity assumed from a practice question. For disposal, choose an authorized route and retain evidence of transfer or destruction rather than placing stock in ordinary trash. The DEA’s disposal resources identify the federal program area; the specific disposal method must fit the registrant and material involved.

Worked example: A sealed bottle of 100 controlled tablets is absent from a delivery. Staff secure the storage area and compare the purchase order, carrier proof, receiving log, and camera or access records. If the bottle was misfiled, they document its recovery and count it. If it remains missing, they assess theft or significant loss and make required reports; they do not enter ‘100 wasted’ without evidence.

Watch the distinction: An inventory adjustment is an accounting entry, not an explanation for missing medicine. Investigate the cause and apply the appropriate loss or disposal process.

Reference: [1]; [3]

55. Prescription records and audit trails

Prescription records must show the authorized order and what the pharmacy actually did with it. Preserve the original prescription, prescriber clarifications, product and quantity dispensed, dates, refills, transfers, and relevant pharmacist decisions for the applicable retention period. An audit trail should identify who entered or changed material information and when. Corrections are additions to a history, not silent replacements of inconvenient facts. Link the patient profile to dispensing events so allergies, interactions, recalls, and later questions can be reconstructed. Restrict access to staff with a legitimate role, but ensure authorized regulators can inspect required records. For electronic systems, backups and migration plans matter because records that technically exist but cannot be retrieved are poor evidence of compliance.

Worked example: After a prescription is dispensed, a technician finds that the patient’s street number was entered incorrectly. The technician corrects the address under their own login. The system keeps the previous value, new value, user, and time while preserving the original dispensing transaction. A later reviewer can see a demographic correction rather than mistakenly inferring that the prescription was rewritten.

Watch the distinction: Overwriting an old entry may make the current screen look tidy, but it removes evidence needed to explain the original dispense and subsequent correction.

56. Setting-specific medication systems

Medication movement differs by setting. In community practice, the pharmacy usually dispenses a patient labeled supply for the patient’s use. Institutional and long term care systems may involve medication orders, unit dose packaging, medication administration records, facility custody, and returns. Identify which party receives the order, verifies it, dispenses or prepares doses, administers them, and records administration. A stop order must reach both the pharmacy’s dispensing workflow and the facility’s administration workflow; changing only one leaves a route for an unintended dose. Reconcile outstanding packages and deliveries, and distinguish an ordered dose from a dose actually given. Returns require assessment of custody and product integrity before any reuse or disposal decision. The pharmacist remains responsible for appropriate pharmacy review within the applicable arrangement.

Worked example: A nursing facility discontinues a resident’s medicine at 2 p.m.; the next scheduled dose is 6 p.m. The pharmacy records the stop, prevents another package from being sent, and confirms the facility has removed the 6 p.m. entry from its administration record. It also accounts for doses already delivered. Stopping future dispensing alone would not prevent tonight’s dose.

Watch the distinction: A discontinued pharmacy order does not prove that nurses received the change. Check the administration record and doses already at the facility.

57. Compounding or manufacturing

Classify a preparation by who it is for, why it is made, how much is made, and where it goes. Traditional patient specific compounding responds to an identified patient’s clinical need, such as a dosage form unavailable commercially. Limited anticipatory preparation may be treated differently from routine production for broad distribution. Preparing repeated batches for unrelated clinics without patient orders raises office use, outsourcing, and manufacturing questions that cannot be solved by calling the work ‘compounding.’ Identify the applicable legal pathway before production, then apply its registration, quality, labeling, and distribution requirements. Also examine whether an essentially commercially available product is being copied and whether the ingredients are lawful for the chosen pathway. North Dakota’s Board identifies pharmaceutical compounding standards among its rules.

Worked example: A pharmacy plans 12 identical batches of 20 syringes each for sale to unrelated clinics, with no identified patient orders. That is 12 × 20 = 240 syringes intended for distribution beyond individual prescriptions. The pharmacy pauses and determines the applicable office use, outsourcing, or manufacturing pathway before making them. Calling the batches ‘anticipatory’ does not by itself establish authority.

Watch the distinction: A preparation made inside a pharmacy is not automatically patient specific compounding. Intended recipients, scale, and distribution can change the governing category.

Reference: [1]

58. Compounding quality controls

Quality controls start before mixing. Confirm a valid formulation, ingredient identity and quality, calculations, equipment suitability, and personnel competence. For sterile work, the environment and aseptic technique add contamination controls; for nonsterile work, the chosen process must still produce a uniform, stable preparation. Keep a record of ingredients and lots, quantities, steps, checks, labeling, and the basis for the assigned beyond use date under the applicable standards. Final review should compare the finished preparation with the prescription and quality criteria, not merely verify that a worksheet was signed. If ingredient identity, sterility assurance, or a critical calculation cannot be supported, quarantine the preparation and resolve the defect before release. A clean room cannot compensate for an unknown ingredient.

Worked example: A sterile batch requires 5 mL of a verified ingredient, but the container’s label is damaged and its lot cannot be matched to receiving records. The compounder sets the container aside and quarantines any preparation already made with it. Staff obtain traceable replacement stock, remake the batch if needed, and document the decision. The measured 5 mL does not establish that the right ingredient was used.

Watch the distinction: Passing an environmental check does not verify ingredient identity. Sterile quality depends on the material, process, environment, and recorded final review together.

Reference: [1]

59. Central fill and remote systems

When prescription processing is split across sites, responsibility must follow each step. Identify which pharmacy receives the prescription, performs clinical review, enters data, fills and verifies the product, produces the patient label, provides counseling, and handles delivery problems. A central fill arrangement may divide these tasks, but it cannot leave a verification step unassigned. Records should connect the originating and filling sites to the same transaction and show the product, lot where relevant, personnel actions, shipment, and final disposition. Remote supervision or automated systems need separate authority and controls for access, communication, and pharmacist intervention. Before using the arrangement, check that each site is authorized for its assigned activity and that the patient can identify whom to contact about the medicine.

Worked example: A local pharmacy accepts an order for 30 tablets and routes it to a central fill site for mailing. The sites establish who completes clinical review, who verifies the 30 tablets and label, and who answers counseling and delivery questions. Their linked records show the same order and shipment. The patient’s North Dakota MPJE practice questions study scenario would be incomplete if either verification role were missing.

Watch the distinction: Sending an order to central fill does not transfer every duty automatically. Assign and document each review, product check, patient communication, and delivery responsibility.

60. Inspections and corrective action

An inspection finding is a starting point for a corrective sequence. First contain immediate risk: segregate expired or suspect stock and stop its use. Define the scope by checking locations, lots, dates, dispensing records, and whether patients may have received affected products. Correct records and notify patients or other parties when the facts require it. Then identify the process failure, such as unclear shelf ownership, missed expiration checks, or a system that failed to block selection. Assign a responsible person and a measurable verification step so the fix can be checked later. Staff training may help, but training alone does not repair a faulty workflow. Keep evidence of quarantine, disposition, patient assessment, procedure changes, and follow-up so an inspector can see both the immediate correction and prevention.

Worked example: An inspector finds eight expired packages among active stock. The pharmacy quarantines all eight, checks dispensing records and finds that one matching lot was supplied last week, then assesses and contacts that patient as appropriate. It documents disposition, changes the shelf check process, and verifies at the next check that no expired packages remain in active locations.

Watch the distinction: Removing expired boxes from the shelf addresses only the visible stock. Check prior dispensing and the process that allowed the products to remain selectable.

Reference: [1]